On the other hand, treatment with doxorubicin was found to increase TF-positive EV shedding in breast cancer cell lines MCF-7 and MDA-MB-231 in vitro, with high doses of doxorubicin resulting in a significant rise in thrombogenic activity of isolated EVs [19]. This evidence concerns the gene TF and breast carcinoma.